Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|November 14, 2013
RFLP markers linked to the root knot nematode resistance gene Mi in tomatoR Klein-Lankhorst, P Rietveld, B Machiels, et al.
The Journal of Supportive Oncology|August 27, 2004
Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practicesH Koeppler, M Duru, M Grundheber, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2016
Follow-up Reality for Breast Cancer Patients - Standardised Survey of Patients and Physicians and Analysis of Treatment DataS Feiten, J Dünnebacke, V Friesenhahn, et al.
The Plant Journal : for Cell and Molecular Biology|November 1, 1992
The root-knot nematode resistance gene (Mi) in tomato: construction of a molecular linkage map and identification of dominant cDNA markers in resistant genotypesJ Y Ho, R Weide, H M Ma, et al.
Leukemia|January 1, 1994
Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomasR Weide, M Tiemann, K H Pflüger, et al.
Genetics|December 1, 1993
Integration of the classical and molecular linkage maps of tomato chromosome 6R Weide, M F van Wordragen, R K Lankhorst, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2018
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network RegistryI Witzel, E Laakmann, R Weide, et al.
ESMO Open|June 2, 2022
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer RegistryE Laakmann, I Witzel, T Neunhöffer, et al.
ESMO Open|April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registryK Riecke, V Müller, T Neunhöffer, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Pageof 6